← Leaderboards
Alok A Khorana
University Of Rochester
$4,905,152
Attributed
$10,640,368
Total exposure
5
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3M · FY2006–25$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,640,368 · 5
By mechanism
U01$4,744,245 · 1
UG3$2,290,286 · 1
R01$2,146,502 · 1
R34$810,470 · 1
K23$648,865 · 1
Top collaborators
- Keith R. Mccrae8 shared
- Claudia Marcela Diaz-Montero3 shared
- Jeffrey Zwicker3 shared
- Jean Marie Connors1 shared
- Paul M. Ridker1 shared
Most similar at University Of Rochester
Same institution · by research overlap
- Justin T Baker$4,497,285
- Joseph D. Rosenblatt$6,445,612
Others in their field
Top investigators on “Thrombosis”
- Paul M. Ridker · Brigham And Women'S Hospital$59,264,235
- John H Griffin · Scripps Research Institute$29,245,116
- David J. Pinsky · University Of Michigan At Ann Arbor$29,054,903
- Bruce Furie · Beth Israel Deaconess Medical Center$28,093,838
- Denisa D Wagner · Boston Children'S Hospital$24,247,974
- Satya P. Kunapuli · Temple University$22,403,131
Research focus
ThrombosisMalignant NeoplasmsProspectiveCancer PatientThromboplastinHigh RiskMorbidity - Disease RateFibrin Fragment DReportingRisk AssessmentBlood CoagulationCohortPredictive ModelingValidationRisk FactorsIncidenceAnticoagulationPreventHemostatic AgentsCancer DiagnosisNovel MarkerP-SelectinPathway InteractionsPrograms
Grant awards (17)
(1/2) Statins to Prevent Cancer Associated Venous Thromboembolism (STAT-CAT): CCC$2,290,286
UG3 · FY2025 · HL
Mechanisms of cancer immunotherapy-associated thrombosis$720,736
R01 · FY2025 · HL
Mechanisms of cancer immunotherapy-associated thrombosis$704,368
R01 · FY2024 · HL
Mechanisms of cancer immunotherapy-associated thrombosis$721,398
R01 · FY2023 · HL
Novel approaches to improve prediction of cancer-associated thrombosis$957,703
U01 · FY2022 · HL
Novel approaches to improve prediction of cancer-associated thrombosis$967,487
U01 · FY2021 · HL
Novel approaches to improve prediction of cancer-associated thrombosis$960,071
U01 · FY2020 · HL
Novel approaches to improve prediction of cancer-associated thrombosis$953,390
U01 · FY2019 · HL
Novel approaches to improve prediction of cancer-associated thrombosis$905,594
U01 · FY2018 · HL
Risk-adapted thromboprophylaxis of hospitalized cancer patients$235,401
R34 · FY2018 · HL
Risk-adapted thromboprophylaxis of hospitalized cancer patients$321,168
R34 · FY2017 · HL
Risk-adapted thromboprophylaxis of hospitalized cancer patients$253,901
R34 · FY2016 · HL
Risk Factors for Venous Thromboembolism in Cancer Patients Receiving Chemotherapy$129,965
K23 · FY2010 · CA · contact PI
Risk Factors for Venous Thromboembolism in Cancer Patients Receiving Chemotherapy$129,165
K23 · FY2009 · CA · contact PI
Risk Factors for Venous Thromboembolism in Cancer Patients Receiving Chemotherapy$129,165
K23 · FY2008 · CA · contact PI
Risk Factors for Venous Thromboembolism in Cancer Patients Receiving Chemotherapy$129,885
K23 · FY2007 · CA · contact PI
Risk Factors for Venous Thromboembolism in Cancer Patients Receiving Chemotherapy$130,685
K23 · FY2006 · CA · contact PI